What it sells
AI-native pharma company
Business model breakdown
Buyer: who owns the budget?
Not a vendor product; pharma-style company partnering with disease foundations (e.g. Alliance to Cure Cavernous Malformation).
Workflow: what inputs become what output?
Autonomous agents find FDA-approved drugs to repurpose for new diseases (e.g. cavernous malformation) and run clinical trials efficiently, including agent-based trial success prediction.
Economics: what it saves and how it charges
Drug developer: monetizes through owning/developing repurposed drug candidates for long-tail diseases where inference cost replaces knowledge-work cost; no revenue figures stated.
Distribution: how it reaches customers
Partnerships with patient foundations and preclinical/clinical collaborators; research published via blog and benchmarks (RepurposingBench, ClinicBench).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.